Abstract Skeletal muscle atrophy can result from prolonged periods of skeletal muscle inactivity due to bed rest, denervation, or unloading. Such unloading-associated atrophy of skeletal muscle is characterized by both an increase in protein degradation and a decrease in protein synthesis. Successful treatments for skeletal muscle atrophy could either block protein degradation pathways activated during atrophy, or stimulate protein synthesis pathways induced during skeletal muscle hypertrophy. In this review, we mainly focus on the Insulin-like growth factor 1 (IGF-1)/Insulin receptor substrate 1 (IRS-1) pathway in muscle, because there is increasing evidence indicating that inhibition of this pathway in muscle is involved in the progression of disuse atrophy. We also focus on the signaling pathways that control skeletal muscle atrophy, including muscle atrophy-associated ubiqitin ligases such as Cbl-b, muscle RING finger 1 (MuRF1), and muscle atrophy F-box (MAFbx)/atrogin-1.
Introduction
Skeletal muscle is the largest organ in the human body, comprising about 40% of total body weight. The mass and composition of skeletal muscle are critical for its function and can be regulated in response to changes in pathological conditions. For example, prolonged periods of skeletal muscle inactivity due to unloading, bed rest, denervation, immortalization or microgravity can result in significant muscle atrophy.
It has been known that decreased protein synthesis and increased protein degradation both contribute to the overall loss of muscle protein due to disuse of skeletal muscle, leading to atrophy. Although the triggers that cause atrophy are different, the loss of muscle mass in each case involves a common program that stimulates muscle proteolysis. Significant advances have been made in our understanding of the proteolytic pathways involved in atrophy.
Over the past few years, advances in cell biology have progressed our understanding of the molecular underpinnings of the proteolytic process, including three recently identified ubiquitin ligases, Cbl-b, MuRF1, and MAFbx/ atrogin-1 [1] [2] [3] [4] . Based on current knowledge of disuse muscle atrophy, we suspect that disuse muscle atrophy is a process that involves the interplay between two or more signaling pathways rather than isolated pathways.
Role of IGF-1 in muscle cell growth and differentiation
Insulin-like growth factor 1 (IGF-1) strongly stimulates mitogenic and myogenic responses, and is required for the development of skeletal muscle 5) . Depending on timing and intracellular conditions, IGF-1 can stimulate both cellular proliferation and differentiation of myogenic cells.
Satellite cells are believed to be a component of the response to mechanical loading because their irradiation followed by a loading stimulus results in an attenuated increase in skeletal muscle mass and protein content 6) . In fact, exercise and increased physical activity increase satellite cell number and IGF-1 synthesis in skeletal muscle cells. Direct administration of IGF-1 into the atrophied muscle results in increased muscle mass and enhanced satellite cell proliferation 7) . In addition to stimulating myoblast proliferation, IGF-1 also stimulates their differentiation 8) . In fact, if the serum concentration in culture medium is decreased from 10% to 0.2%, myoblasts differentiate into myocytes and form myotubes in response to IGF-1 9) . Thus, IGF-1 stimulates precursor cells to divide and differentiating myoblasts to form postmitotic myonuclei. For example, under most in vitro conditions, high IGF-1 concentrations favor proliferation, whereas lower IGF-1 concentrations seem to promote differentiation 5) . IGF-1 therefore is an important mitogen and differentiation factor for skeletal muscle cells.
IGF-1 also alters transcription and translation of muscle factors that regulate myocyte growth or differentiation [10] [11] . For example, IGF-1 inhibits production of myogenin, a protein that stimulates muscle cell differentiation, thus allowing increased myoblast proliferation. However, its effects are biphasic because prolonged exposure to IGF-1 results in increased myogenin expression, thus *Correspondence: kondoshi@nutr.med.tokushima-u.ac.jp facilitating differentiation 12) . IGF-1 also modulates the expression of MyoD, myocyte enhancer factor-2 and p21 to control differentiation. These responses seem to be coordinated, allowing IGF-1 to regulate both myoblast expansion and number, thus resulting in an increase in muscle fiber size.
IGF-1 signal transduction pathways in skeletal muscle pathophysiology
The endocrine, autocrine and paracrine functions of IGF-1 are mediated through binding to the IGF-1 receptor (IGF-1R), which is a ligand-activated receptor tyrosine kinase. The binding of IGF-1 to IGF-1R induces autophosphorylation, which recruits specific cytoplasmic molecules containing the insulin receptor substrate (IRS) proteins. IRS proteins play critical roles in the proliferative and differentiative actions of IGF-1. IRS-1 serves as a mediator and docking protein for other downstream signaling molecules in skeletal muscle cells. Phosphotyrosine residues of IRS-1 are recognized by the SH2 domain containing a signaling molecule. These binding interactions lead to the activation of downstream signaling cascades, including PI3-kinase pathways. Active PI3-kinase generates phosphatidylinositol 3,4,5 trisphosphate, resulting in activation of Ser/Thr kinase, Akt. Activated Akt phosphorylates various substrates, including GSK3 β, FOXO1 and S6 kinase (S6K). Phosphorylation of these substrates is known to play important roles in expression of a variety of IGF-1 bioactivities.
In the signal transduction of the IGF-1/IGF-1R system, IRS-1 protein levels can define IGF-1 signaling intensity [13] [14] [15] . Treatment with proinflammatory cytokine, glucocorticoids or retinoic acid was all reported to decrease the IRS-1 protein level [16] [17] [18] , resulting in suppression of IGF-1 signal activity. These conditions induced the interaction of IRS-1 with ubiquitin ligases including Cbl-b, SOCS1, SOCS3, and Mdm2, leading to degradation of IRS-1 [16] [17] [18] [19] [20] . Thus, IGF-1 signaling is abrogated, resulting in muscle cell atrophy.
Regulation of skeletal muscle protein balance by IGF-1R/IRS-1 signaling pathway
Recent findings in the field of skeletal muscle biology have revealed how general physiological processes, such as changes in the rate of total body protein synthesis or breakdown, use IGF-1/IRS-1 pathways to regulate muscle mass and function. These findings include a crosstalk between the intracellular signaling pathways involved in energy balance and protein synthesis, and delineation of molecular pathways involved in protein breakdown. Many of these processes are influenced by IGF-1 signaling. Therefore, factors that control the ability of IGF-1 to stimulate myoblast proliferation or myotube protein synthesis are all important variables for regulating the balance between maintenance of muscle mass and atrophy.
In addition to stimulating protein synthesis, IGF-1 inhibits protein breakdown. Pathophysiologic processes, such as high doses of exogenous glucocorticoids, sepsis and inflammation, lead to muscle breakdown, which reduces IGF-1 expression in muscle cells and serum, and results in muscle atrophy. In fact, administration of exogenous IGF-1 can partially reverse such atrophy 21) . Recent studies have shown that there are some important connections between the deactivation of the IGF-1/ IRS-1/PI3K/Akt pathway and activation of muscle-specific proteolytic genes, including atrophy-related ubiquitin ligases (atrogenes). The IGF-1 signal not only stimulates muscle protein synthesis through the activation of IRS-1, but also reduces the expression of the atrogenes.
Role of FOXOs in IRS-1/PI3K/Akt pathway and muscle atrophy
Activation of the IRS-1/PI3K/Akt pathway results in the phosphorylation of the FOXO proteins, a subgroup of the Forkhead family of transcription factors. Mammalian cells contain three members of this family, FOXO1, FOXO3, and FOXO4, which have been implicated in regulation of target genes involved in metabolism, apoptosis, and muscle atrophy 22) . Akt phosphorylates FOXO transcription factors, leading to inhibition of their transcriptional functions through exclusion of phosphorylated FOXO proteins from the nucleus to cytoplasm 22) . Dephosphorylation of FOXO factors can enter the nucleus and transactivate their target genes 22) . A recent report showed that the IGF-1/IRS-1/PI3K/Akt pathway critically suppressed FOXO activity through suppression of their translocation into the nucleus. When the active, nuclear-localized mutant form of FOXO was introduced into cells, IGF-1 could no longer block the MuRF1 or MAFbx up-regulation induced by glucocorticoids. This finding demonstrated that the anti-atrophy activity of the IGF1/IRS-1/PI3K/Akt pathway required the blockade of FOXOs. Therefore, FOXOs were negatively involved in IGF-1-mediated suppression of muscle atrophy 23) .
Atrophy and transcriptional regulation
The pioneer studies on gene expression, profiling different models of muscle atrophy, identified a subset of genes that are commonly up-or down-regulated in atrophying muscle. Since all the diseases and conditions used for the microarray experiments (i.e., diabetes, cancer cachexia, chronic renal failure, fasting, denervation, and space flight) have muscle atrophy in common, the commonly up-or down-expressed genes are believed to regulate the loss of muscle components and are called atrophy-related genes or atrogenes 24) . These findings indicate that muscle atrophy is an active process controlled by specific signaling pathways and transcriptional programs. Furthermore, the three most induced genes are novel ubiquitin ligases, atrogin-1, MuRF1 and Cbl-b, that are upregulated in different models of muscle atrophy and are responsible for the increased protein degradation through the ubiquitinproteasome system 25) .
Occurrence of skeletal muscle atrophy via induction of distinct E3 ubiquitin ligases
Differential expression screening studies, designed to identify markers of the atrophy process, identified three genes whose expression increased significantly in multiple models of skeletal muscle atrophy: (1) for Muscle Ring Finger1 (MuRF1), (2) for Muscle Atrophy F-box (MAFbx), also called Atrogin-1, (3) and for Cblb. MuRF1, atrogin-1 and Cbl-b are E3 ubiquitin ligases, and their expression is markedly increased after denervation, disuse atrophy or treatment with glucocorticoids. Upregulation of these three E3 ligases can be antagonized by IGF-1 treatment, leading to inhibition of proteasome formation.
Ubiquitination of target proteins requires the activation of three distinct enzymatic components, an E1 ubiquitinactivating enzyme, an E2 ubiquitin-conjugating enzyme, and an E3 ubiquitin-ligating enzyme 25) . The E3 ubiquitin ligases are the components which confer substrate specificity. Several hundred distinct E3s have been identified, and it is likely that each modulates the ubiquitination of a distinct set of substrates. Thus, the regulation of ubiquitination can be part of a coordinated signaling pathway, analogous to phosphorylation, in which key pathways might be activated by the enhanced proteolysis of a key inhibitor protein, or in which pathways might be inactivated via the degradation of an activating enzyme.
The involvement of the ubiquitin-proteasome pathway in skeletal muscle atrophy had been well-established as follows: Rates of protein breakdown increase during atrophy; inhibition of the proteasome blocks this increase 26) ; the amount of polyubiquitin conjugation per total protein measured increases during atrophy; mRNA levels of genes, which encode distinct components of the ubiquitin pathway, increase during atrophy 27) . MuRF1 encodes a protein which contains three domains: a RING-finger domain, which is required for ubiquitin-ligase activity, a "B-box," domain whose function is unclear, and a "coiled-coil" domain, which may be required for the formation of heterodimers between MuRF1 and a related protein, MuRF2. Proteins which have these three domains have been called RBCC (RING, B-box, coiled-coil domains) proteins or TRIM (tripartite motif) proteins. MuRF1 has been demonstrated to have ubiquitin-ligase activity, which depends on the presence of the RING domain for that activity. As for substrates, it was recently shown that MuRF1 could induce the ubiquitination of the cardiac form of Troponin I, indicating that MuRF1 may act by degrading components of the contractile apparatus. MuRF1 has been shown to bind to the myofibrillar protein titin, at the M-line. Overexpression of MuRF1 results in the disruption of the subdomain of titin that binds MuRF1, suggesting that MuRF1 may play a role in titin turnover 28) . MuRF1 has also been demonstrated to exist in the nucleus, and indications that it interacts with transcription-regulating elements such as GMEB1 suggest a potential role for MuRF1 in modulating transcription. This has not yet been demonstrated.
MAFbx/Atrogin-1 contains an F-box domain, a characteristic motif seen in a family of E3 ubiquitin ligases called SCFs (for Skp1, Cullin, F-box) 29) . F-box proteins, containing E3 ligases, usually bind to a substrate only after that substrate has first been post-translationally modified, for example by phosphorylation 29) . This suggests the possibility of a signaling pathway in which a potential substrate is first phosphorylated as a response to an atrophy-induced stimulus, and then degraded via MAFbx. Recently, substrates have been suggested for MAFbx, including MyoD 30) . However, it has not yet been demonstrated if either protein is ubiquitinated by MAFbx in skeletal muscle or under atrophic conditions. Knockout mice studies show that MuRF1-null or MAFbx-null mice appear phenotypically normal. However, under atrophic conditions, those knockout mice showed resistance to loss of muscle mass in comparison to littermate controls 1) . This finding demonstrated for the first time that inhibition of discrete ubiquitin ligases could modulate the amount of muscle lost after an atrophyinducing stimulus. Therefore, MuRF1 or MAFbx may constitute targets for pharmacologic intervention. They may also serve as early markers of skeletal muscle atrophy, aiding in the diagnosis of muscle disease.
Cbl-b is another muscle atrophy-associated E3 ubiqutin ligase. It is important to note that Cbl-b is significantly induced and activated in response to unloading stresses, and specifically to ubiquitinates IRS-1 (Fig. 1) . Loss of IRS-1 results in the activation of FOXO-dependent induction of MuRF1 and atrogin-1. Thus, Cbl-b-dependent silencing of IRS-1 expression is one of the critical mechanisms of unloading-induced muscle atrophy. In fact, Cbl-bdeficient mice show a significant resistance to unloadinginduced atrophy and loss of muscle function 31) . There are additional E3 ubiquitin ligases, which may play important roles in skeletal muscle atrophy. For example, a protein called E3-alphaII was shown to be enriched in skeletal muscle, and its expression is positively regulated by proinflammatory cytokines, which can induce skeletal muscle atrophy. During progression of cancer cachexia, E3-alphaII mRNA levels were induced, accompanied by an increase in protein ubiquitination 32) . Whether loss of E3-alphaII in any way perturbs the course of muscle atrophy remains to be established; however, it may be important downstream of the breakdown of the contractile apparatus, because it has been implicated as an N-end rule ubiquitin ligase, which would presumably be necessary to break down contractile apparatus proteins clipped by other proteases 32) .
IRS-1/PI3K/AKT and mTOR as an additional downstream mediator
Several lines of evidence indicated that the Akt/mTOR pathway was additionally required for much of the IGF-1 mediated transcriptional changes in skeletal muscle cells. Pharmacologic inhibition of PI3K using LY294002, which acts upstream of Akt, or inhibition of mTOR using RAP, which acts downstream of Akt, caused decreases in myotube size stimulated by IGF-1. Inhibition of PI3K by LY294002 completely inhibited the IGF-1-induced hypertrophy, while inhibition of mTOR by RAP treatment partially blocked the hypertrophy induced by IGF-1. Of the IGF-1 regulated genes that were blocked by LY294002, all but 1% were also blocked when treated with RAP, suggesting that the Akt/mTOR pathway downstream of PI3K was additionally required to mediate transcription activation by IGF-1. Furthermore, the mTOR signaling did not involve phosphorylation of the FOXO transcription factors, indicating that an additional step of IGF-1 transcriptional regulation occurs downstream of mTOR, which is independent of FOXO. Thus both the Akt/FOXO and the Akt/mTOR pathways are required for the transcriptional changes induced by IGF-1, and there may be multiple checkpoints of atrophy signaling downstream of PI3K/Akt activation 33) .
